McKesson (NYSE:MCK) Updates FY 2025 Earnings Guidance

McKesson (NYSE:MCK) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 31.250-32.050 for the period, compared to the consensus EPS estimate of 31.020. The company issued revenue guidance of $355.3 billion-$361.5 billion, compared to the consensus revenue estimate of $340.6 billion.

McKesson Trading Up 2.1 %

MCK opened at $544.53 on Wednesday. McKesson has a 1-year low of $364.08 and a 1-year high of $546.63. The company has a market cap of $71.56 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.41 and a beta of 0.45. The company’s fifty day moving average price is $531.17 and its two-hundred day moving average price is $493.81.

McKesson (NYSE:MCK) last posted its earnings results on Tuesday, May 7th. The company reported $6.18 earnings per share for the quarter, missing analysts’ consensus estimates of $6.34 by ($0.16). The business had revenue of $76.36 billion during the quarter, compared to analyst estimates of $79.32 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $7.19 EPS. As a group, equities analysts forecast that McKesson will post 27.59 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Friday, May 31st. This represents a $2.48 annualized dividend and a dividend yield of 0.46%. McKesson’s payout ratio is 11.24%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on MCK shares. SVB Leerink started coverage on McKesson in a research note on Monday, February 26th. They set an outperform rating and a $600.00 price objective on the stock. Robert W. Baird raised their price target on shares of McKesson from $603.00 to $671.00 and gave the company an outperform rating in a research report on Wednesday. UBS Group upped their price objective on shares of McKesson from $575.00 to $620.00 and gave the stock a buy rating in a research report on Wednesday, March 6th. Argus increased their price objective on shares of McKesson from $510.00 to $570.00 and gave the company a buy rating in a research note on Wednesday, April 10th. Finally, StockNews.com raised shares of McKesson from a buy rating to a strong-buy rating in a report on Saturday. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $550.71.

Insider Buying and Selling at McKesson

In related news, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Brian S. Tyler sold 3,473 shares of McKesson stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the completion of the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at $22,789,074.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the transaction, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.